Alligator Bioscience AB (ATORX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alligator Bioscience AB (ATORX) has a cash flow conversion efficiency ratio of -3.791x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-26.00 Million ≈ $-2.80 Million USD) by net assets (Skr6.86 Million ≈ $738.14K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Alligator Bioscience AB to measure how much of total assets are equity-financed.
Alligator Bioscience AB - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Alligator Bioscience AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Alligator Bioscience AB to evaluate the quality of earnings relative to operating cash generation.
Alligator Bioscience AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alligator Bioscience AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Presidio Property Trust
NASDAQ:SQFT
|
-0.038x |
|
Precomp Solutions AB Series B
ST:PCOM-B
|
-0.069x |
|
CN Energy Group Inc
NASDAQ:CNEY
|
-0.005x |
|
Induct AS
OL:INDCT
|
N/A |
|
Public Policy Holding Company Inc
LSE:PPHC
|
-0.107x |
|
Khandwala Securities Limited
NSE:KHANDSE
|
-0.051x |
|
Toys R US ANZ Ltd
AU:TOY
|
0.426x |
|
iSpecimen Inc
NASDAQ:ISPC
|
-4.130x |
Annual Cash Flow Conversion Efficiency for Alligator Bioscience AB (2011–2025)
The table below shows the annual cash flow conversion efficiency of Alligator Bioscience AB from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Alligator Bioscience AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr6.86 Million ≈ $738.14K |
Skr-155.99 Million ≈ $-16.79 Million |
-22.742x | -1498.03% |
| 2024-12-31 | Skr-130.59 Million ≈ $-14.05 Million |
Skr-212.43 Million ≈ $-22.86 Million |
1.627x | +110.19% |
| 2023-12-31 | Skr11.86 Million ≈ $1.28 Million |
Skr-189.28 Million ≈ $-20.37 Million |
-15.967x | -723.75% |
| 2022-12-31 | Skr89.05 Million ≈ $9.58 Million |
Skr-172.61 Million ≈ $-18.58 Million |
-1.938x | -330.70% |
| 2021-12-31 | Skr282.27 Million ≈ $30.38 Million |
Skr-127.03 Million ≈ $-13.67 Million |
-0.450x | +63.31% |
| 2020-12-31 | Skr115.24 Million ≈ $12.40 Million |
Skr-141.35 Million ≈ $-15.21 Million |
-1.227x | -77.16% |
| 2019-12-31 | Skr258.50 Million ≈ $27.82 Million |
Skr-178.96 Million ≈ $-19.26 Million |
-0.692x | -211.41% |
| 2018-12-31 | Skr468.31 Million ≈ $50.40 Million |
Skr-104.11 Million ≈ $-11.20 Million |
-0.222x | -37.90% |
| 2017-12-31 | Skr617.96 Million ≈ $66.50 Million |
Skr-99.63 Million ≈ $-10.72 Million |
-0.161x | -189.86% |
| 2016-12-31 | Skr676.18 Million ≈ $72.77 Million |
Skr-37.61 Million ≈ $-4.05 Million |
-0.056x | -110.78% |
| 2015-12-31 | Skr396.97 Million ≈ $42.72 Million |
Skr204.89 Million ≈ $22.05 Million |
0.516x | +156.37% |
| 2014-12-31 | Skr68.52 Million ≈ $7.37 Million |
Skr-62.74 Million ≈ $-6.75 Million |
-0.916x | +43.36% |
| 2011-12-31 | Skr21.51 Million ≈ $2.31 Million |
Skr-34.77 Million ≈ $-3.74 Million |
-1.617x | -- |
About Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using N… Read more